Low Affinity FcgR Deficient Mice
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsLynn Macdonald, Naxin Tu, Cagan Gurer, Sean Stevens, Andrew J. Murphy
Life of this patent
Estimating the term…
Abstract
Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity FcγR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low affinity human FcγR genes from the endogenous FcγR locus, and wherein the mice comprise a functional FcRγ-chain. Genetically modified mice that express up to five low affinity human FcγR genes on accessory cells of the host immune system are provided.
Claims20
A genetically modified mouse that does not express an endogenous FcγRIIB α-chain, an endogenous FcγRIV α-chain, and an endogenous FcγRIII α-chain.
A genetically modified mouse comprising a deletion of an endogenous FcγRIIB α-chain gene, an endogenous FcγRIV α-chain gene, and a deletion of an endogenous FcγRIII α-chain gene.
A genetically modified non-human cell comprising a deletion of an endogenous FcγRIIB α-chain gene, an endogenous FcγRIV α-chain gene, and a deletion of an endogenous FcγRIII α-chain gene.
Dependencies are inferred from the claim text.